LIVIVO - Search results -

Search results

Result 1 - 10 of total 49

Search options

Article ; Online: Favorable outcome of non-myeloablative allogeneic transplantation in adult patients with severe sickle cell disease: A single center experience of 200 patients.

Damlaj, Moussab / Alahmari, Bader / Alaskar, Ahmed / Alhejazi, Ayman / Alsadi, Husam / Ahmed, Mazin / Alanazi, Tahani / Ahmed, Rasha / Alharbi, Amani / Shehabeddine, Inaam / Alzaidi, Afnan / Alkhuraisat, Suha / Mahassnah, Isam / Alquraan, Hamza / Ballili, Maybelle / Alzahrani, Mohsen

American journal of hematology

2024 Volume 99, Issue 6, Page(s) 1023–1030

Abstract: Allogeneic hematopoietic stem cell transplant (HSCT) for adults with severe sickle cell disease (SCD) is potentially curative but not commonly utilized therapy due to complications such as graft failure (GF) and organ toxicity. Herein, we are reporting ... ...

Abstract	Allogeneic hematopoietic stem cell transplant (HSCT) for adults with severe sickle cell disease (SCD) is potentially curative but not commonly utilized therapy due to complications such as graft failure (GF) and organ toxicity. Herein, we are reporting our long-term outcome data of non-myeloablative (NMA) HSCT in adults with severe SCD with emphasis on factors predicting event free survival (EFS). Adults with severe SCD undergoing NMA match-related donor allogeneic HSCT from 2015 to 2021 with at least 12 months of follow-up were included. A total of 200 patients were included with a median age of 26 years (14-43) and 56% were male. The median infused CD34 dose was 13.7 (5.07-25.8), respectively. Median absolute neutrophil count engraftment was 19 (13-39) days with 51% of patients receiving GCSF to expedite recovery. A total of 17 patients experienced GF; 3 as primary and 14 as secondary within a median time of 204 days (40-905). A 76% successfully discontinued sirolimus at the last follow-up. Median follow-up for the cohort is 29.2 (2.1-71.4) months. Estimated 3-year EFS and OS were 88.2% (81.9-92.5) and 94.6% (89.2-97.3). At multivariable analysis, minor ABC incompatibility hazard ratio (HR) 4 (1.3-12.1; 0.014) and allo-antibody against non-ABO donor antigens HR 4.3 (1.3-14.1; 0.016) were significant for EFS. No clonal evolution or myeloid malignancies were seen. This largest single-center report of NMA HSCT in adults with severe SCD further delineated its feasibility, potential toxicities, and fertility outcomes. GF remains a major impediment and appears dependent on ABO matching and non-ABO antibodies.
MeSH term(s)	Humans ; Adult ; Male ; Female ; Anemia, Sickle Cell/therapy ; Hematopoietic Stem Cell Transplantation/methods ; Adolescent ; Young Adult ; Transplantation, Homologous ; Treatment Outcome ; Transplantation Conditioning/methods ; Graft vs Host Disease/etiology ; Follow-Up Studies ; Retrospective Studies ; Allografts
Language	English
Publishing date	2024-03-15
Publishing country	United States
Document type	Journal Article
ZDB-ID	196767-8
ISSN	1096-8652 ; 0361-8609
ISSN (online)	1096-8652
ISSN	0361-8609
DOI	10.1002/ajh.27295
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 1251: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾

Article ; Online: Venetoclax in combination with carfilzomib and dexamethasone in relapsed/refractory multiple myeloma harboring t(11,14)(q13;q32): two case reports and a review of the literature.

Abuelgasim, Khadega A / Alherz, Noha / Alhejazi, Ayman / Damlaj, Moussab

Journal of medical case reports

2020 Volume 14, Issue 1, Page(s) 54

Abstract: Background: Multiple myeloma has witnessed significant advances due to the approval of many novel agents. However, in spite of all these new developments, multiple myeloma remains an incurable disease with inevitable relapse in the majority of patients. ...

Abstract	Background: Multiple myeloma has witnessed significant advances due to the approval of many novel agents. However, in spite of all these new developments, multiple myeloma remains an incurable disease with inevitable relapse in the majority of patients. Venetoclax is a selective antiapoptotic protein B-cell lymphoma 2 inhibitor that induces cell death in multiple myeloma cells, particularly in those harboring t(11,14)(q13;q32). We report two cases of patients with multiple myeloma with t(11,14)(q13;q32) who were treated with venetoclax/carfilzomib/dexamethasone with rapid initial response; however, the response was short-lived. Cases presentation: Patient 1 was a 50-year-old Saudi man with International Staging System stage III kappa light chain multiple myeloma with normal karyotype diagnosed in May 2013. He received bortezomib/thalidomide/dexamethasone treatment and underwent autologous hematopoietic stem cell transplant. Three years later, he presented with disease progression and received multiple lines of chemotherapy, including carfilzomib/lenalidomide/dexamethasone. Venetoclax/carfilzomib/dexamethasone was started after acquiring t(11,14)(q13;q32) 5 years into his disease course. He achieved complete remission, with disease progression after cycle 6. Patient 2 was a 48-year-old Saudi man with International Staging System stage III immunoglobulin G kappa multiple myeloma with t(11,14)(q13;q32) diagnosed in May 2017. He received bortezomib/thalidomide/dexamethasone treatment and underwent autologous hematopoietic stem cell transplant. Eighteen months later, he had disease progression, and he received multiple lines of chemotherapy, including carfilzomib/dexamethasone. He was shifted to venetoclax/carfilzomib/dexamethasone in April 2019 and had an initial clinical response; two months later, he progressed to plasma cell leukemia with rapid deterioration to multiorgan failure. Conclusions: Acquired t(11;14)(q13;q32) is unreported in the multiple myeloma literature. In the era of targeted therapy, it is essential to repeat the cytogenetic and multiple myeloma fluorescence in situ hybridization panel with each disease progression. Multiple myeloma remains a challenging hematological malignancy despite advances in personalized/precision medicine.
MeSH term(s)	Antineoplastic Agents/therapeutic use ; Antineoplastic Combined Chemotherapy Protocols ; Bridged Bicyclo Compounds, Heterocyclic/therapeutic use ; Dexamethasone/therapeutic use ; Fatal Outcome ; Hematopoietic Stem Cell Transplantation ; Humans ; Male ; Middle Aged ; Multiple Myeloma/drug therapy ; Multiple Myeloma/therapy ; Neoplasm Recurrence, Local ; Oligopeptides/therapeutic use ; Remission Induction/methods ; Sulfonamides/therapeutic use
Chemical Substances	Antineoplastic Agents ; Bridged Bicyclo Compounds, Heterocyclic ; Oligopeptides ; Sulfonamides ; carfilzomib (72X6E3J5AR) ; Dexamethasone (7S5I7G3JQL) ; venetoclax (N54AIC43PW)
Language	English
Publishing date	2020-04-23
Publishing country	England
Document type	Case Reports ; Journal Article ; Review
ZDB-ID	2269805-X
ISSN	1752-1947 ; 1752-1947
ISSN (online)	1752-1947
ISSN	1752-1947
DOI	10.1186/s13256-020-02376-y
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Erdheim-Chester Disease Successfully Treated with Front-Line Single-Agent Dabrafenib.

Salama, Hind / Fahed Alzayed, Mohammed / Alharbi, Khalid Ghazi / Khattak, Zohra / Omer, Mohamed H / Tahir, Leena / ALhejazi, Ayman

The American journal of case reports

2022 Volume 23, Page(s) e935090

Abstract: BACKGROUND Erdheim-Chester disease (ECD) is a clonal disease characterized by histiocytic infiltration of multiple organ systems. As ECD is a rare disorder with variable presentations, its diagnosis and management can present a significant clinical ... ...

Abstract	BACKGROUND Erdheim-Chester disease (ECD) is a clonal disease characterized by histiocytic infiltration of multiple organ systems. As ECD is a rare disorder with variable presentations, its diagnosis and management can present a significant clinical challenge. The diagnosis of ECD requires several clinical, radiological, and histological criteria. Since approximately 75% of ECD patients harbor a mutation in the proto-oncogene BRAF V600E, inhibition of BRAF activation by BRAF inhibitors has significantly improved the management of ECD. Vemurafenib was approved by the U.S. Food and Drug administration for treatment of BRAF-mutated ECD. Another BRAF inhibitor, dabrafenib, has been used in some cases as a single agent and was associated with a lower toxicity profile. CASE REPORT We report the case of a 30-year-old Saudi Arabian woman who initially presented with a history of diffuse abdominal pain and fever. The patient had elevated inflammatory markers, and radiological investigations revealed hypermetabolic regions in the frontoparietal brain lobe, anterior pericardium, kidneys, and the anterior abdominal wall. Histological investigations from the right perinephric soft-tissue mass revealed foamy histiocytes associated with mild chronic inflammation. Furthermore, BRAF V600E was mutated in the biopsy sample, leading to a diagnosis of BRAF-mutated ECD. The patient began single-agent dabrafenib therapy at 75 mg twice daily and experienced an excellent clinical and radiological response with no reported toxicity. CONCLUSIONS Single-agent dabrafenib is effective and well tolerated among ECD patients; therefore, it might be considered as a first-line option for the treatment of BRAF-mutated ECD.
MeSH term(s)	Adult ; Erdheim-Chester Disease/diagnosis ; Erdheim-Chester Disease/drug therapy ; Erdheim-Chester Disease/genetics ; Female ; Humans ; Imidazoles ; Mutation ; Oximes/therapeutic use ; Proto-Oncogene Proteins B-raf/genetics ; Proto-Oncogene Proteins B-raf/therapeutic use ; Saudi Arabia
Chemical Substances	Imidazoles ; Oximes ; Proto-Oncogene Proteins B-raf (EC 2.7.11.1) ; dabrafenib (QGP4HA4G1B)
Language	English
Publishing date	2022-02-16
Publishing country	United States
Document type	Case Reports ; Journal Article
ZDB-ID	2517183-5
ISSN	1941-5923 ; 1941-5923
ISSN (online)	1941-5923
ISSN	1941-5923
DOI	10.12659/AJCR.935090
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Real-World Registry on the Pharmacotherapy of Multiple Myeloma and Associated Renal and Pulmonary Impairments in the Greater Gulf Region: Protocol for a Retrospective Real-World Data Study.

Nourallah, Abdulnaser / Alshehri, Abdulrahman / Alhejazi, Ayman / Usman, Binyam / ElGohary, Ghada / Malhan, Hafiz / Motabi, Ibraheem / Al Farsi, Khalil / Alshuaibi, Mohammed / Siddiqui, Mustaqeem / Ghonema, Rasha / Taha, Ruba Yasin / Abouzeid, Tarek / Ahmed, Wesam / Diab, Mohanad / Alhuraiji, Ahmad / Rabea, Magdy / Chouikrat, Mohamed Zahir

JMIR research protocols

2024 Volume 13, Page(s) e49861

Abstract: Background: Multiple myeloma (MM) is the second-most common cancer among hematological malignancies. Patients with active disease may experience several comorbidities, including renal insufficiency and asthma, which may lead to treatment failure. The ... ...

Abstract	Background: Multiple myeloma (MM) is the second-most common cancer among hematological malignancies. Patients with active disease may experience several comorbidities, including renal insufficiency and asthma, which may lead to treatment failure. The treatment of relapsed or refractory MM (RRMM) has been associated with multiple factors, causing a decline in progression-free survival as well as overall survival with subsequent lines of therapy. Data about the characteristics of this group of patients in the Greater Gulf region are lacking. Objective: The primary objective of this study is to describe the disease characteristics and various treatment approaches or regimens used in the management of patients with RRMM in the Greater Gulf region. Methods: We will conduct a regional, retrospective study collecting real-world and epidemiological data on patients with MM in countries of the Greater Gulf region. Medical records will be used to obtain the required data. Around 150 to 170 patients' records are planned to be retrospectively reviewed over 6 months without any cross-sectional or prospective intervention. Cases will be collected from Saudi Arabia, the United Arab Emirates, Kuwait, Oman, and Qatar. Descriptive as well as analytical statistics will be performed on the extracted data. The calculated sample size will allow us to estimate the percentages of RRMM cases with acceptable precision while complying with the challenges in light of data scarcity. We will obtain a comprehensive description of the demographic profile of patients with MM; treatment outcomes; the proportion of patients with MM with renal impairment and asthma, chronic obstructive pulmonary disease, or both at the time of diagnosis and any subsequent point; and data related to treatment lines, regimens, and MM-associated morbidities. Results: Patient medical records were reviewed between June 2022 and January 2023 for eligibility and data extraction. A total of 148 patients were eligible for study inclusion, of whom 64.2% (n=95) were male and 35.8% (n=53) were female. The study is currently in its final stages of data analysis. The final manuscript is expected to be published in 2024. Conclusions: Although MM is a predominant hematological disease, data on its prevalence and patients' characteristics in the Greater Gulf region are scarce. Therefore, this study will give us real-world insights into disease characteristics and various management approaches of patients with MM in the Greater Gulf region. International registered report identifier (irrid): DERR1-10.2196/49861.
MeSH term(s)	Adult ; Aged ; Female ; Humans ; Male ; Middle Aged ; Middle East/epidemiology ; Multiple Myeloma/drug therapy ; Multiple Myeloma/epidemiology ; Multiple Myeloma/complications ; Registries/statistics & numerical data ; Renal Insufficiency/epidemiology ; Retrospective Studies ; Research Design
Language	English
Publishing date	2024-04-24
Publishing country	Canada
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	2719222-2
ISSN	1929-0748 ; 1929-0748
ISSN (online)	1929-0748
ISSN	1929-0748
DOI	10.2196/49861
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Outcome of Oncology Patients Infected With Coronavirus.

Jazieh, Abdul-Rahman / Alenazi, Thamer H / Alhejazi, Ayman / Al Safi, Faisal / Al Olayan, Ashwaq

JCO global oncology

2020 Volume 6, Page(s) 471–475

Abstract: Purpose: This study investigated the features of oncology patients with confirmed Middle East respiratory syndrome (MERS) at the Ministry of National Guard Health Affairs-Riyadh during the outbreak of June 2015 to determine the clinical course and ... ...

Abstract	Purpose: This study investigated the features of oncology patients with confirmed Middle East respiratory syndrome (MERS) at the Ministry of National Guard Health Affairs-Riyadh during the outbreak of June 2015 to determine the clinical course and outcome of affected patients. Methods: The patients' demographic information, cancer history, treatment pattern, information about MERS-coronavirus (CoV) infection, history of travel, clinical symptoms, test results, and outcome were collected and analyzed as part of a quality improvement project to improve the care and safety of our patients. Only patients with confirmed infection were included. Results: A total of 19 patients were identified, with a median age of 66 years (range, 16-88 years), and 12 patients (63%) were males. The most common underlying disease was hematologic malignancies (47.4%), followed by colorectal cancer (21%) and lung cancer (15.8%). Hypertension and diabetes mellitus were the most common comorbidities (57.9% and 52.6%, respectively). Infection was diagnosed by nasopharyngeal swab in all patients. All patients contracted the infection during their hospitalization for other reasons. Sixteen patients (80%) were admitted to the intensive care unit; 13 patients (81%) had acute respiratory distress syndrome, 11 were intubated (68.75%), 9 had acute renal injury (56.25%), and 3 required dialysis (18.75%). Only 3 patients (15.8%) with early-stage cancers survived. Patients with hematologic malignancies and advanced solid tumors had a 100% case fatality rate. The majority of the causes of death were due to multi-organ failure and septic shock. Conclusion: MERS-CoV infection resulted in a high case fatality rate in patients with malignancy. Therefore, it is critical to implement effective primary preventive measures to avoid exposure of patients with cancer to the virus.
MeSH term(s)	Adolescent ; Adult ; Aged ; Aged, 80 and over ; Comorbidity ; Coronavirus Infections/epidemiology ; Coronavirus Infections/etiology ; Coronavirus Infections/mortality ; Coronavirus Infections/therapy ; Disease Outbreaks ; Female ; Humans ; Intensive Care Units ; Male ; Middle Aged ; Neoplasms/mortality ; Neoplasms/virology ; Renal Dialysis ; Retrospective Studies ; Saudi Arabia/epidemiology ; Travel ; Treatment Outcome ; Young Adult
Keywords	covid19
Language	English
Publishing date	2020-03-02
Publishing country	United States
Document type	Journal Article
ISSN	2687-8941
ISSN (online)	2687-8941
DOI	10.1200/GO.20.00064
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Brentuximab vedotin containing salvage followed by consolidation post autologous hematopoietic stem cell transplantation in high risk relapsed refractory classical Hodgkin lymphoma.

Damlaj, Moussab / Abuelgasim, Khadega A / Alhejazi, Ayman / Alahmari, Bader / Alaskar, Ahmed / Alzahrani, Mohsen

Bone marrow transplantation

2020 Volume 55, Issue 12, Page(s) 2322–2325

MeSH term(s)	Brentuximab Vedotin ; Hematopoietic Stem Cell Transplantation ; Hodgkin Disease/therapy ; Humans ; Neoplasm Recurrence, Local ; Salvage Therapy ; Stem Cell Transplantation ; Transplantation, Autologous
Chemical Substances	Brentuximab Vedotin (7XL5ISS668)
Language	English
Publishing date	2020-05-13
Publishing country	England
Document type	Letter
ZDB-ID	632854-4
ISSN	1476-5365 ; 0268-3369 ; 0951-3078
ISSN (online)	1476-5365
ISSN	0268-3369 ; 0951-3078
DOI	10.1038/s41409-020-0935-0
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 2168: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article: Promising remissions in relapsed refractory classical Hodgkin lymphoma patients requiring multiple salvage regimens before transplantation in the brentuximab vedotin era.

Abuelgasim, Khadega A / Ghazi, Samer / Alahmari, Bader / Alhejazi, Ayman / Alaskar, Ahmed / Alzahrani, Mohsen / Damlaj, Moussab

Leukemia research reports

2021 Volume 16, Page(s) 100276

Abstract: Relapsed/refractory classical Hodgkin lymphoma (R/R cHL) patients refractory to first line salvage have poor outcomes. Herein we report the outcome of R/R cHL patients requiring ≥two vs. one line in the era of chemo-immunotherapy. Among 55 R/R cHL ... ...

Abstract	Relapsed/refractory classical Hodgkin lymphoma (R/R cHL) patients refractory to first line salvage have poor outcomes. Herein we report the outcome of R/R cHL patients requiring ≥two vs. one line in the era of chemo-immunotherapy. Among 55 R/R cHL patients, 33 (60%) required one, 22 (40%) required ≥two lines. At 2 years, the estimated PFS and OS for patients requiring one vs. ≥two lines was 71.2% (50.1-84.7) vs. 51.9% (27.6-71.6),
Language	English
Publishing date	2021-10-21
Publishing country	Netherlands
Document type	Journal Article
ZDB-ID	2706248-X
ISSN	2213-0489
ISSN	2213-0489
DOI	10.1016/j.lrr.2021.100276
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article: Impact of cluster of differentiation 20 expression and rituximab therapy in classical Hodgkin lymphoma: Real world experience.

Abuelgasim, Khadega A / Shammari, Raed Al / Alshieban, Saeed / Alahmari, Bader / Alzahrani, Mohsen / Alhejazi, Ayman / Alaskar, Ahmed / Damlaj, Moussab

Leukemia research reports

2021 Volume 15, Page(s) 100240

Abstract: The prognostic impact of CD20 expression and rituximab therapy in classical Hodgkin lymphoma (cHL) is unclear. Among 310 patients, CD20 was expressed in 66 (22%) cases. The 3-year PFS was 75.1% for ... ...

Abstract	The prognostic impact of CD20 expression and rituximab therapy in classical Hodgkin lymphoma (cHL) is unclear. Among 310 patients, CD20 was expressed in 66 (22%) cases. The 3-year PFS was 75.1% for CD20
Language	English
Publishing date	2021-04-08
Publishing country	Netherlands
Document type	Journal Article
ZDB-ID	2706248-X
ISSN	2213-0489
ISSN	2213-0489
DOI	10.1016/j.lrr.2021.100240
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Therapeutic Potential of Checkpoint Inhibitors in Refractory Plasmablastic Lymphoma.

Damlaj, Moussab / Alzayed, Mohammed / Alahmari, Bader / Alhejazi, Ayman / Alaskar, Ahmed / Alzahrani, Mohsen

Clinical lymphoma, myeloma & leukemia

2019 Volume 19, Issue 10, Page(s) e559–e563

MeSH term(s)	Adult ; Allografts ; Antineoplastic Agents, Immunological/therapeutic use ; B7-H1 Antigen/antagonists & inhibitors ; B7-H1 Antigen/metabolism ; Drug Resistance, Neoplasm ; Drug Therapy/methods ; Female ; Humans ; Nivolumab/therapeutic use ; Plasmablastic Lymphoma/diagnostic imaging ; Plasmablastic Lymphoma/drug therapy ; Plasmablastic Lymphoma/pathology ; Positron Emission Tomography Computed Tomography/methods ; Programmed Cell Death 1 Receptor/antagonists & inhibitors ; Programmed Cell Death 1 Receptor/metabolism ; Stem Cell Transplantation/methods ; Treatment Outcome
Chemical Substances	Antineoplastic Agents, Immunological ; B7-H1 Antigen ; Programmed Cell Death 1 Receptor ; Nivolumab (31YO63LBSN)
Language	English
Publishing date	2019-06-26
Publishing country	United States
Document type	Case Reports ; Journal Article
ZDB-ID	2540992-X
ISSN	2152-2669 ; 2152-2650
ISSN (online)	2152-2669
ISSN	2152-2650
DOI	10.1016/j.clml.2019.06.008
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 5903: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article: Erdheim-Chester Disease with No Skeletal Bone Involvement and Massive Weight Loss.

Salama, Hind / Kojan, Suleiman / Abdulrahman, Shaima / Azzumeea, Fahad / Alhejazi, Ayman

Case reports in hematology

2017 Volume 2017, Page(s) 3862052

Abstract: Erdheim-Chester disease (ECD) is a rare type of non-Langerhans cell histiocytosis, with only 550 cases reported worldwide. ECD is characterized by diffuse histiocytic infiltration of multiorgans. The age of presentation of this disease is typically ... ...

Abstract	Erdheim-Chester disease (ECD) is a rare type of non-Langerhans cell histiocytosis, with only 550 cases reported worldwide. ECD is characterized by diffuse histiocytic infiltration of multiorgans. The age of presentation of this disease is typically between 40 and 70 years. Bone disease is the most common symptom, as unique radiological findings of long bone sclerosis occur in 96% of cases. Furthermore, BRAF V600E mutation is detected in 60% of ECD cases. In this manuscript, we are describing a unique case of ECD; the patient is younger than most reported cases and has no bone pain or any skeletal involvement. This patient has unintentionally lost about 50% of his body mass and is suffering from progressive cerebellar manifestations with radiological evidence of cerebellar atrophy, in contrast to the usual ECD manifestation of cerebellar infiltration. In addition, the patient has cardiac, retroperitoneal, and perinephric involvement, but he retains his sexual drive and fertility. A tissue biopsy from the retroperitoneal mass displayed typical morphological and immunohistochemical features of ECD, and BRAF V600E mutation was detected. He was treated with pegylated interferon alpha, but his disease progressed and the treatment was changed to vemurafenib to which he had an excellent response at 6 weeks.
Language	English
Publishing date	2017-10-30
Publishing country	United States
Document type	Case Reports
ZDB-ID	2627639-2
ISSN	2090-6579 ; 2090-6560
ISSN (online)	2090-6579
ISSN	2090-6560
DOI	10.1155/2017/3862052
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

To top

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito